Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

MACC1 regulates Fas mediated apoptosis through STAT1/3 - Mcl-1 signaling in solid cancers.

Radhakrishnan H, Ilm K, Walther W, Shirasawa S, Sasazuki T, Daniel PT, Gillissen B, Stein U.

Cancer Lett. 2017 Sep 10;403:231-245. doi: 10.1016/j.canlet.2017.06.020. Epub 2017 Jun 23.

PMID:
28649004
2.

HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells.

Lee DH, Sung KS, Bartlett DL, Kwon YT, Lee YJ.

Cell Signal. 2015 Feb;27(2):293-305. doi: 10.1016/j.cellsig.2014.11.013. Epub 2014 Nov 18.

3.

Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells.

Huang S, Sinicrope FA.

Mol Cancer Ther. 2010 Mar;9(3):742-50. doi: 10.1158/1535-7163.MCT-09-1004. Epub 2010 Mar 2.

5.

JAK/STAT pathway plays a critical role in the proinflammatory gene expression and apoptosis of RAW264.7 cells induced by trichothecenes as DON and T-2 toxin.

Wang X, Liu Q, Ihsan A, Huang L, Dai M, Hao H, Cheng G, Liu Z, Wang Y, Yuan Z.

Toxicol Sci. 2012 Jun;127(2):412-24. doi: 10.1093/toxsci/kfs106. Epub 2012 Mar 27.

PMID:
22454431
6.

Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.

El Fajoui Z, Toscano F, Jacquemin G, Abello J, Scoazec JY, Micheau O, Saurin JC.

Gastroenterology. 2011 Aug;141(2):663-73. doi: 10.1053/j.gastro.2011.04.055. Epub 2011 Apr 30.

PMID:
21683075
7.

Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.

Kawakami H, Huang S, Pal K, Dutta SK, Mukhopadhyay D, Sinicrope FA.

Mol Cancer Ther. 2016 Dec;15(12):3015-3027. Epub 2016 Oct 7.

8.

Oncostatin M-dependent Mcl-1 induction mediated by JAK1/2-STAT1/3 and CREB contributes to bioenergetic improvements and protective effects against mitochondrial dysfunction in cortical neurons.

Chang SH, Hwang CS, Yin JH, Chen SD, Yang DI.

Biochim Biophys Acta. 2015 Oct;1853(10 Pt A):2306-25. doi: 10.1016/j.bbamcr.2015.05.014. Epub 2015 May 15.

9.

Repression of Mcl-1 and disruption of the Mcl-1/Bak interaction in myeloma cells couple ER stress to mitochondrial apoptosis.

Gomez-Bougie P, Halliez M, Moreau P, Pellat-Deceunynck C, Amiot M.

Cancer Lett. 2016 Dec 28;383(2):204-211. doi: 10.1016/j.canlet.2016.09.030. Epub 2016 Sep 30.

PMID:
27697610
10.

Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.

Goodwin CM, Rossanese OW, Olejniczak ET, Fesik SW.

Cell Death Differ. 2015 Dec;22(12):2098-106. doi: 10.1038/cdd.2015.73. Epub 2015 Jun 5.

11.

The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.

Sung ES, Park KJ, Choi HJ, Kim CH, Kim YS.

Exp Cell Res. 2012 Aug 1;318(13):1564-76. doi: 10.1016/j.yexcr.2012.04.003. Epub 2012 Apr 10.

PMID:
22513214
12.
13.

A novel requirement for Janus kinases as mediators of drug resistance induced by fibroblast growth factor-2 in human cancer cells.

Carmo CR, Lyons-Lewis J, Seckl MJ, Costa-Pereira AP.

PLoS One. 2011;6(5):e19861. doi: 10.1371/journal.pone.0019861. Epub 2011 May 20.

15.

Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.

Amigo-Jiménez I, Bailón E, Aguilera-Montilla N, Terol MJ, García-Marco JA, García-Pardo A.

Oncotarget. 2015 Dec 29;6(42):44832-48. doi: 10.18632/oncotarget.6265.

16.

Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma.

Gillissen B, Wendt J, Richter A, Richter A, Müer A, Overkamp T, Gebhardt N, Preissner R, Belka C, Dörken B, Daniel PT.

J Cell Biol. 2010 Mar 22;188(6):851-62. doi: 10.1083/jcb.200912070.

17.
18.

BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells.

Huang S, Okumura K, Sinicrope FA.

Clin Cancer Res. 2009 Jan 1;15(1):150-9. doi: 10.1158/1078-0432.CCR-08-1575.

19.

Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis.

Clohessy JG, Zhuang J, de Boer J, Gil-Gómez G, Brady HJ.

J Biol Chem. 2006 Mar 3;281(9):5750-9. Epub 2005 Dec 27.

20.

Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy.

Cruickshanks N, Hamed HA, Booth L, Tavallai S, Syed J, Sajithlal GB, Grant S, Poklepovic A, Dent P.

Cancer Biol Ther. 2013 Oct 1;14(10):982-96. doi: 10.4161/cbt.26234. Epub 2013 Aug 22.

Supplemental Content

Support Center